| |
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now.
|
|
|
Tuesday, January 14, 2025 | 10am ET / 7am PT This webinar highlights the FDA’s discussion paper on health equity in medical devices, investments in inclusive product design and clinical trials, and provider programs educating patients about managing chronic conditions. Register now and discover strategies for fostering equitable access to quality care and improving outcomes for diverse populations.
|
|
| By Eric Sagonowsky Each year at the J.P. Morgan Healthcare Conference, pharma CEOs are tasked with assuring and convincing investors that they’ve positioned their companies to overcome expected challenges. Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on. |
|
|
|
By Ben Adams Gilead continues its divergence out of its original infectious disease beginnings and into cancer and, now, more deeply than before, into inflammation, penning a major $1.7 billion deal with dermatology specialist Leo Pharma just a few days before the J.P. Morgan Healthcare Conference. |
By Kevin Dunleavy Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s closing price of Intra-Cellular, a New York City based biotech that develops and markets products for the central nervous system. |
By Angus Liu Roche has about $10 billion in M&A firepower it can deploy every year, but it’s “not just going to spend money,” the company’s pharma CEO Teresa Graham said at the J.P. Morgan Healthcare Conference. |
|
Wednesday, February 26, 2025 | 1pm ET / 10am PT This webinar reveals how to harness their combined power to reach and engage your target audience, with actionable insights into how brands can leverage these emerging spaces in new ways. Register now.
|
|
By Nick Paul Taylor Eli Lilly is reenergizing its attempt to challenge Novartis and Roche for a breast cancer market, kicking off the J.P. Morgan Healthcare Conference with a deal to buy Scorpion Therapeutics’ PI3Kα pipeline for up to $2.5 billion. |
By Fraiser Kansteiner,Zoey Becker,Angus Liu,Kevin Dunleavy,Eric Sagonowsky While the overall volume of pharma and life sciences M&A activity was healthy in 2024 versus historic levels, deals trended toward the smaller side, reducing the total deal value observed for the year. That inclination for large pharma companies to pursue small and mid-sized transactions is likely to persist in 2025, too, analysts at Leerink Partners and PwC have opined. |
By Fraiser Kansteiner,Kevin Dunleavy Like many other biopharma companies presenting at this year’s J.P. Morgan Healthcare Conference, Eli Lilly took a chance on Tuesday to share its preliminary sales results for 2024. Unfortunately for the company, however, the early glimpse at its fourth-quarter performance doesn’t seem to be going over well with investors. |
By Conor Hale The blood sugar tracking company offered a preliminary look at its annual and fourth-quarter earnings report at the J.P. Morgan Healthcare Conference in San Francisco. |
By Kevin Dunleavy One day after Samsung Biologics revealed in a regulatory filing that it had signed its largest contract in company history, the CDMO giant said it's considering the construction of a sixth manufacturing plant. |
By Darren Incorvaia Spanish pharma giant Grifols is leveraging its massive collection of plasma samples to look for early biomarkers of Parkinson’s disease (PD) thanks to a $21 million grant from the Michael J. Fox Foundation for Parkinson’s Research. |
By Nick Paul Taylor Y-mAbs Therapeutics is parting ways with its chief commercial officer and putting a new hire in charge of the cancer drug Danyelza. The biotech made the changes, which include “a small adjustment” to the commercial team, as part of a rethink that could put 13% of its employees out of work. |
Fierce podcastsDon’t miss an episode |
| | Price transparency has been a regulatory priority over the past several years. While providers have had time to adapt and adjust, there remain common challenges that many run into as they look to comply with regulatory requirements. |
|
|---|
|
|
|
Life sciences companies face the challenge of meeting today’s performance, innovation, and competitive requirements while preparing for the unknown. Access this report to learn how to adopt the right approaches to achieve true organizational transformation by leveraging a wide array of data sources alongside a digitization strategy. Download now.
|
|
| ResearchStudy shows significant Rx growth using new EHR marketing technique. Sponsored by: Veradigm |
| WhitepaperHow can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
